Zymeworks (ZYME) Free Cash Flow Growth (1y) (2022 - 2026)
Powered by 
Analysis
Zymeworks (ZYME) Free Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 31.57% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 58.53% |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - | -374.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -374.85% |
| Mar 31, 2026 | -1,216.92% |
| Dec 31, 2025 | 74.08% |
| Sep 30, 2025 | -369.42% |
| Jun 30, 2025 | 145.43% |
| Mar 31, 2025 | 90.79% |
| Dec 31, 2024 | -408.05% |
| Sep 30, 2024 | 84.45% |
| Jun 30, 2024 | -255.31% |
| Mar 31, 2024 | 54.70% |
| Dec 31, 2023 | -95.85% |
| Sep 30, 2023 | 41.08% |
| Jun 30, 2023 | 87.47% |
| Mar 31, 2023 | -40.30% |
| Dec 31, 2022 | 691.43% |